Overview Dividends

(COO) The Cooper Companies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2166485019

Contact Lenses, Fertility Devices, Intrauterine Devices, Surgical Instruments

COO EPS (Earnings per Share)

EPS Growth (3Y CAGR): -70.97%
EPS Trend (3Y Correlation): -83.2%

COO Revenue

Revenue Growth (3Y CAGR): 8.46%
Revenue Trend (3Y Correlation): 94.2%

Risk via 10d forecast
Volatility	31.4%
Value at Risk 5%th	46.5%
Relative Tail Risk	-10.02%

Reward TTM
Sharpe Ratio	-0.93
Alpha	-42.29

Character TTM
Hurst Exponent	0.328
Beta	0.785
Beta Downside	0.653

Drawdowns 3y
Max DD	42.17%
Mean DD	13.75%
Median DD	9.81%

Description: COO The Cooper Companies October 30, 2025

The Cooper Companies (NASDAQ:COO) operates through two distinct businesses: CooperVision, which designs and sells a broad portfolio of contact lenses-including toric, multifocal, and spherical lenses-to address astigmatism, presbyopia, myopia, and other refractive errors across the Americas, Europe, the Middle East, Africa, and Asia-Pacific; and CooperSurgical, which focuses on family- and women-health products such as fertility consumables, intra-uterine contraceptive devices, cryostorage services, and genomic testing, sold to healthcare professionals and institutions worldwide.

In fiscal 2023, CooperVision generated roughly $3.0 billion in revenue, driven by a 12% year-over-year increase in myopia-control lens sales-a segment benefiting from rising myopia prevalence among children and young adults. CooperSurgical contributed about $1.2 billion, with fertility-related services growing at a compound annual growth rate (CAGR) of 9% since 2020, reflecting global demand for assisted-reproductive technologies and expanding cord-blood banking. Both segments are sensitive to macro-economic factors such as discretionary consumer spending, insurance reimbursement policies, and demographic trends (e.g., aging populations increasing demand for presbyopic lenses).

For a deeper quantitative assessment of COO’s valuation dynamics, you may find the ValueRay platform’s analyst tools useful for exploring forward-looking cash-flow models and peer-group benchmarks.

COO Stock Overview

Market Cap in USD	13,937m
Sub-Industry	Health Care Supplies
IPO / Inception	1983-12-30
Return 12m vs S&P 500	-38.2%
Analyst Rating	4.05 of 5

COO Dividends

Currently no dividends paid

COO Growth Ratios

CAGR 3y	-1.80%
CAGR/Max DD Calmar Ratio	-0.04
CAGR/Mean DD Pain Ratio	-0.13
Current Volume	2754.6k
Average Volume	1960.8k

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (407.8m TTM) > 0 and > 6% of Revenue (6% = 242.7m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA 1.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 27.87% (prev 25.16%; Δ 2.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 816.3m > Net Income 407.8m (YES >=105%, WARN >=100%)

Net Debt (2.35b) to EBITDA (1.09b) ratio: 2.16 <= 3.0 (WARN <= 3.5)

Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (200.6m) change vs 12m ago 0.0% (target <= -2.0% for YES)

Gross Margin 66.96% (prev 66.36%; Δ 0.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 33.05% (prev 31.42%; Δ 1.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.45 (EBITDA TTM 1.09b / Interest Expense TTM 111.7m) >= 6 (WARN >= 3)

Altman Z'' 4.86

(A) 0.09 = (Total Current Assets 2.14b - Total Current Liabilities 1.01b) / Total Assets 12.38b

(B) 0.61 = Retained Earnings (Balance) 7.56b / Total Assets 12.38b

(D) 1.79 = Book Value of Equity 7.19b / Total Liabilities 4.02b

Total Rating: 4.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.55

1. Piotroski 7.50pt = 2.50

2. FCF Yield 2.53% = 1.26

3. FCF Margin 10.18% = 2.55

4. Debt/Equity 0.30 = 2.46

5. Debt/Ebitda 2.16 = -0.31

6. ROIC - WACC (= -4.19)% = -5.23

7. RoE 4.97% = 0.41

8. Rev. Trend 94.24% = 7.07

9. EPS Trend -83.17% = -4.16

What is the price of COO shares?

As of November 14, 2025, the stock is trading at USD 71.75 with a total of 2,754,625 shares traded.
Over the past week, the price has changed by +3.99%, over one month by +3.54%, over three months by -3.39% and over the past year by -29.57%.

Is The Cooper Companies a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, The Cooper Companies is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.55 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COO is around 60.62 USD . This means that COO is currently overvalued and has a potential downside of -15.51%.

Is COO a buy, sell or hold?

The Cooper Companies has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy COO.

Strong Buy: 9
Buy: 2
Hold: 8
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the COO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	83	15.7%
Analysts Target Price	83	15.7%
ValueRay Target Price	67.6	-5.8%

COO Fundamental Data Overview November 10, 2025

Market Cap USD = 13.94b (13.94b USD * 1.0 USD.USD)
P/E Trailing = 34.3627
P/E Forward = 15.9744
P/S = 3.4448
P/B = 1.6452
P/EG = 0.8676
Beta = 1.06
Revenue TTM = 4.05b USD
EBIT TTM = 720.9m USD
EBITDA TTM = 1.09b USD
Long Term Debt = 2.43b USD (from longTermDebt, last quarter)
Short Term Debt = 47.8m USD (from shortTermDebt, last quarter)
Debt = 2.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.35b USD (from netDebt column, last quarter)
Enterprise Value = 16.29b USD (13.94b + Debt 2.48b - CCE 124.9m)
Interest Coverage Ratio = 6.45 (Ebit TTM 720.9m / Interest Expense TTM 111.7m)
FCF Yield = 2.53% (FCF TTM 411.9m / Enterprise Value 16.29b)
FCF Margin = 10.18% (FCF TTM 411.9m / Revenue TTM 4.05b)
Net Margin = 10.08% (Net Income TTM 407.8m / Revenue TTM 4.05b)
Gross Margin = 66.96% ((Revenue TTM 4.05b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = 65.26% (prev 67.75%)
Tobins Q-Ratio = 1.32 (Enterprise Value 16.29b / Total Assets 12.38b)
Interest Expense / Debt = 1.02% (Interest Expense 25.4m / Debt 2.48b)
Taxrate = 35.29% (53.6m / 151.9m)
NOPAT = 466.5m (EBIT 720.9m * (1 - 35.29%))
Current Ratio = 2.12 (Total Current Assets 2.14b / Total Current Liabilities 1.01b)
Debt / Equity = 0.30 (Debt 2.48b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.16 (Net Debt 2.35b / EBITDA 1.09b)
Debt / FCF = 5.71 (Net Debt 2.35b / FCF TTM 411.9m)
Total Stockholder Equity = 8.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.29% (Net Income 407.8m / Total Assets 12.38b)
RoE = 4.97% (Net Income TTM 407.8m / Total Stockholder Equity 8.21b)
RoCE = 6.77% (EBIT 720.9m / Capital Employed (Equity 8.21b + L.T.Debt 2.43b))
RoIC = 4.34% (NOPAT 466.5m / Invested Capital 10.76b)
WACC = 8.52% (E(13.94b)/V(16.41b) * Re(9.92%) + D(2.48b)/V(16.41b) * Rd(1.02%) * (1-Tc(0.35)))
Discount Rate = 9.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.25%
[DCF Debug] Terminal Value 68.71% ; FCFE base≈322.8m ; Y1≈276.2m ; Y5≈214.6m
Fair Price DCF = 14.57 (DCF Value 2.90b / Shares Outstanding 198.8m; 5y FCF grow -17.55% → 3.0% )
EPS Correlation: -83.17 | EPS CAGR: -70.97% | SUE: -4.0 | # QB: 0
Revenue Correlation: 94.24 | Revenue CAGR: 8.46% | SUE: -0.23 | # QB: 0

Additional Sources for COO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle